Erlotinib Tablet
Product Images NDC 68382-915

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Erlotinib (NDC 68382-915). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (E715a711 283a 4662 8df0 D3b86ac5a042 01)

Chemical structure of Erlotinib hydrochloride showing the molecular arrangement of the active ingredient in this prescription drug product by Zydus Pharmaceuticals USA Inc.*

FDA Label Image

Image (E715a711 283a 4662 8df0 D3b86ac5a042 02)

A Kaplan-Meier curve displaying progression-free survival probability over duration in months. Two survival curves are shown, one for chemotherapy and one for Erlotinib, with the x-axis representing months and the y-axis showing probability from 0 to 1. A table below the graph lists the number of patients at risk over time for both treatment groups.*

FDA Label Image

Image (E715a711 283a 4662 8df0 D3b86ac5a042 03)

A Kaplan-Meier curve chart showing overall survival probability over time in months. The chart compares two groups labeled Placebo and Erlotinib, with survival probability on the y-axis and overall survival duration in months on the x-axis. The chart includes patient risk numbers at various time intervals for both groups.*

FDA Label Image

Image (E715a711 283a 4662 8df0 D3b86ac5a042 04)

A Kaplan-Meier survival curve chart depicting overall survival in months (x-axis) versus survival probability (y-axis). Two lines represent patient groups: one receiving Erlotinib and the other placebo, with patient counts at risk listed below the x-axis for both groups.*

FDA Label Image

Image (E715a711 283a 4662 8df0 D3b86ac5a042 05)

A survival curve line graph depicting overall survival probability over months, comparing Erlotinib to placebo. The x-axis shows overall survival in months up to 36 months, and the y-axis shows survival probability from 0 to 1. Below the graph is a table indicating the number of patients at risk for placebo and Erlotinib groups at various time points.*

FDA Label Image

Image (E715a711 283a 4662 8df0 D3b86ac5a042 06)

Erlotinib Tablets 25 mg oral dosage form label showing a blister pack segment with 30 tablets. The label includes dosage strength, manufacturer Cadila Healthcare Ltd. India, and distributor Zydus Pharmaceuticals USA Inc. Directions mention 25 mg erlotinib equivalent per tablet and storage conditions. The label also features the Zydus logo and a barcode on the left.*

FDA Label Image

Image (E715a711 283a 4662 8df0 D3b86ac5a042 07)

Label for Erlotinib Tablets 100 mg produced by Zydus Pharmaceuticals USA Inc. The label displays the NDC number 68382-914-06, an image of a round tablet embossed with '914', and states the package contains 30 tablets for oral use. It includes storage instructions, manufacturing details by Cadila Healthcare Ltd. in India, and distribution by Zydus Pharmaceuticals USA in New Jersey.*

FDA Label Image

Image (E715a711 283a 4662 8df0 D3b86ac5a042 08)

Erlotinib Tablets 150 mg oral tablets packaging label showing product name, strength, and dosage form. The label includes NDC 68382-915-06, manufacturer Cadila Healthcare Ltd., and distributor Zydus Pharmaceuticals USA Inc. It states 30 tablets per container with Rx only designation and storage instructions. A tablet image with the imprint '915' and a barcode are visible.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.